AAP
PCRX icon

Ardsley Advisory Partners’s Pacira BioSciences PCRX Stock Holding History

Ardsley Advisory Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-160,000
Closed -$4.58M – 169
2024
Q2 		$4.58M Buy
+160,000
New +$4.55M 0.67% 51
2024
Q1 		– Sell
-123,400
Closed -$4.16M – 170
2023
Q4 		$4.16M Sell
123,400
-25,600
-17% -$749K 0.64% 42
2023
Q3 		$4.57M Buy
+149,000
New +$5.37M 1.02% 36

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Ardsley Advisory Partners's PCRX Position: Q3 2024 in Review

Ardsley Advisory Partners sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 580,000 shares — an estimated $16.6M sold.

Ardsley Advisory Partners first reported a position in PCRX in Q1 2022 and held it in 7 quarters. The position peaked at $16.6M in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Ardsley Advisory Partners reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Ardsley Advisory Partners sold 580,000 Pacira BioSciences shares in Q3 2024, an estimated $16.6M.
  • Ardsley Advisory Partners first reported a position in Pacira BioSciences in Q1 2022 and held it in 7 quarters.
  • Ardsley Advisory Partners's Pacira BioSciences position peaked at $16.6M in Q2 2024.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Ardsley Advisory Partners's 13F filing for Q3 2024, filed 14 Nov 2024.